

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

VOLUNTARY ANNOUNCEMENT UPDATED INFORMATION OF THE GROUP'S PRODUCTS

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors of the Company is pleased to announce that it was notified by China State Food and Drug Administration that the application of the Group's insulin glargin finished product for the specification of disposable pen-type was approved with the approval number of S20173001. It is expected that the relevant insulin product will be launched to the market soon.

Insulin glargin is a long-acting insulin analog of the third generation insulin products. The Group's insulin glargin finished product for the specification of refilled pen-type has been approved recently (details set out in the Company's announcement on 6 January 2017). So far the Group owned two specifications of insulin glargin finished products. The refilled pen-type should be combined with the injection pen which can be reused. The disposable pen-type with one injection vial is non-refillable and can be injected directly, and thus is disposed after use. Therefore, it is much more convenient to carry and use.

The Group is the pharmaceutical enterprise of the second and third generation insulin products in China. It is expected that the Group's insulin pipeline will be enriched and will bring considerable return to the Company and its shareholders in future.

On behalf of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 1 February 2017

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.